Location History:
- Palo Alto, CA (US) (2016)
- Belmont, CA (US) (2018 - 2024)
Company Filing History:
4 out of 15 
3 out of 5,311 
2 out of 45 
Years Active: 2016-2025
Title: Emily Piccione Griffin: Innovator in Cancer Treatment
Introduction
Emily Piccione Griffin is a prominent inventor based in Belmont, California. She has made significant contributions to the field of cancer treatment through her innovative research and development of antibodies. With a total of seven patents to her name, Griffin is recognized for her groundbreaking work in the medical and pharmaceutical industries.
Latest Patents
Among her latest patents are the anti-CD73 antibodies, which are designed to inhibit CD73 activity and are useful for cancer treatment. These antibodies include amino acid substitution embodiments that affect the glycosylation state of the antibody. Additionally, she has developed humanized anti-CD73 antibodies, specifically the humanized 1E9 antibodies, which are capable of binding CD73. These humanized antibodies are also aimed at treating cancer and include nucleic acids encoding the antibodies, along with methods for inhibiting cell proliferation.
Career Highlights
Emily has worked with notable organizations such as Corvus Pharmaceuticals, Inc. and Leland Stanford Junior University. Her work in these institutions has allowed her to advance her research and collaborate with other experts in the field.
Collaborations
Some of her notable coworkers include Richard A. Miller and Ravindra Majeti, who have contributed to her research endeavors.
Conclusion
Emily Piccione Griffin is a trailblazer in the development of innovative cancer treatments through her patented antibodies. Her work continues to impact the medical field significantly, showcasing her dedication to improving patient outcomes.